XtalPi Inc, a Chinese pharmaceutical firm that uses artificial intelligence (AI) to accelerate the development of new drugs, announced on Monday that it has garnered $318.8 million in a Series C round of financing.
The Series C round was jointly led by SoftBank Vision Fund 2, PICC Capital, an alternative investment platform of Chinese government-owned insurer PICC Group, and Chinese early-stage venture capital firm Morningside Venture Capital.
